Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Consumer Products
Amyris exits vitamin E in deal with DSM
by Melody M. Bomgardner
April 26, 2019
| A version of this story appeared in
Volume 97, Issue 17
Biobased specialty firm Amyris will wrap up a years-long vitamin E deal by selling its royalty rights to partner DSM for $57 million. Amyris will no longer be in the vitamin E business, but the two firms will continue to work together. In 2017, Amyris sold its plant in Brotas, Brazil, to DSM. Now DSM will produce Amyris’s molecules for markets including flavors and fragrances, skin care, sweeteners, and cannabinoids. That deal will be worth up to $40 million over the next 3 years, Amyris says.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X